Bevacizumab and Erlotinib Study in Advanced Ovarian Cancer

Part of paid clinical trials in Tucson, Arizona.

Sponsor
University of Arizona
Study ID
NCT00130520
Phase
PHASE2
Status
Completed

Conditions

Eligibility Criteria

Sex
FEMALE
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • bevacizumab — DRUG
    10mg/kg every two weeks IV-bevacizumab
  • erlotinib — DRUG
    150mg daily by mouth-erlotinib

Study Details

The purpose of this project is to determine if a new combination of drugs, erlotinib (Tarceva™) and bevacizumab is safe and effective for treating women diagnosed with ovarian cancer whose cancer has progressed while on prior standard chemotherapy treatment with a taxane (paclitaxel or docetaxel) and a platinum (cisplatin or carboplatin).

Key Dates

First listed
Aug 15, 2005
Start date
Jun 30, 2005
Status verified
Dec 2010
Primary completion
Jan 31, 2010
Completion
May 31, 2010

Study Design

Enrollment
40 participants (actual)
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: open label

Primary Outcome Measure

Objective Response (Complete Partial, Stable and Progression) [ Time Frame: 06.16.2005 to 10.05.2009 ]

Locations (1)

FacilityCityStateZIPSite coordinators
University of Arizona Cancer CenterTucsonArizona85724-

Find similar trials in Tucson, AZ

By condition
Ovarian cancer
By specialty
OncologyGynecologic oncologyWomen's health
By research site
University of Arizona Cancer Center· Tucson, AZ

Related Studies